Mania Risk on Psychedelics

The risk is real, but small, and some are more vulnerable

STUDY: Eskinazi M et al, Molecular Psychiatry 2026; 

STUDY TYPE: Systematic review and meta-analysis

FUNDING: Independent

Background

As psychedelics like psilocybin, LSD, ayahuasca, and MDMA are moving into clinical trials for mood and anxiety disorders, this systematic review looks at the risk of mania.

The Study

• Systematic review of randomized controlled trials, observational cohorts, cross-sectional surveys, and national registry studies.
• Four registry-based cohort studies (N = 7,478) contributed to a meta-analysis of diagnostic transition to bipolar disorder.

Results

Rates of psychedelic-associated manic or hypomanic symptoms ranged from 6% in controlled psilocybin trials to 30% in naturalistic studies of people with bipolar disorder (which likely captures manias not induced by psychedelics). When mania occurred, it was almost always acute and short-lived.

The pooled rate of transition to a formal bipolar diagnosis following hallucinogen-related psychopathology was 4% (95% CI 2–8%), with no signal that hallucinogens drove this rate above what other substances produce. Cannabis and stimulants carried higher conversion rates.

Those at higher risk:

• People with bipolar I disorder
• Family history of bipolar disorder
• High genetic liability for psychosis

Unsupervised or illegal use roughly doubled the danger. In controlled clinical trials with screened bipolar II patients, no persistent mania emerged.

Practice Implications

1. The risk of mood destabilization is difficult to estimate.
2. Watch for it, and use mood stabilizers in bipolar disorder to prevent it.